Ranier's Compounding Laboratory is recalling 294 units of various compounded medications, including eye solutions, injectable treatments, and inhalation drugs, because they may not be sterile. The recall was initiated because the laboratory's manufacturing practices could not guarantee that products intended to be sterile were free from contamination. These products include common medications like Atropine and Avastin as well as specialized injections, and were distributed primarily within Pennsylvania.
If a drug intended for injection or use in the eye is not sterile, it can introduce bacteria or other contaminants directly into the body. This poses a significant risk of serious infections, which could lead to permanent organ damage or life-threatening complications.
Drug recall baseline remedy
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.